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Abstract
This paper aims at reporting on the design of polymeric drug nanocarriers used in cancer therapy, with a special emphasis on the control of
their biodistribution. First, the prominent role of poly(ethylene oxide) in the lifetime of nanocarriers circulating in the blood stream is high-
lighted, and the origin of a passive targeting based on a difference in the anatomy of tumors and normal tissues is discussed. The main
body of the review is devoted to the targeting of nanocarriers towards tumors and the underlying concepts. As a rule, either the constitutive
polymer is stimuli-responsive and the locus of drug release is where the stimulation occurs, or a ligand endowed with specific recognition is
grafted onto the nanocarrier. Finally, the fate of the nanocarrier after drug delivery and the bioelimination of the polymer(s) involved are briefly
considered.
 2007 Elsevier Ltd.
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Performances of drug delivery systems are continuously
improved with the purpose to maximize therapeutic activity
and to minimize undesirable side-effects. Indeed, the short-
comings of the conventional administration of drugs (tablets,
injections.) are well-known. Lack of selectivity in drug
delivery is a major limitation that may cause profound damage
to healthy tissues. Nowadays, nanocarriers based on amphi-
philic copolymers are able to target specific tissues and to
control the drug biodistribution, particularly in tumoral tissues.
Although this topic will be the focus of this review, it is only
a part of the requirements that a drug delivery system must
satisfy for being of practical interest. Indeed, the pharmaco-
kinetics of the drug may not be ignored for the system to be
biofunctional. For being effective, the administrated drug
must be released at a constant predetermined rate that
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Open access under CC BY-NC-ND license.maintains the drug level in the therapeutic zone. The ideal
release profile is schematized in Fig. 1. Although crucial,
this aspect of the drug release and targeting will not be
discussed further.
Various types of carriers with a size of several tens of
nanometers have been developed [1e12]. Let us mention
polymeric micelles, polymer-based nanoparticles and lipo-
somes. Polymeric micelles are supramolecular assemblies of
amphiphilic block copolymers with a coreeshell structure
(Fig. 2A). Nanoparticles or nanospheres designate solid cores
of biodegradable hydrophobic polymers protected by an am-
phiphilic block copolymer that stabilize their dispersion in
aqueous media (Fig. 2B). Liposomes are vesicles consisting
of one or more phospholipidic bilayer(s), with an aqueous
core (Fig. 2C). Ideally, these nanocarriers should be able to
travel safely throughout the vascular system, to reach the
intended target at full drug content, where they should act
selectively on diseased cells and tissues, without creating
undesired side-effects.
Nevertheless, the natural defences of the body trigger a se-
quence of formidable obstacles on the drug’s pathway to the
7432 K. Van Butsele et al. / Polymer 48 (2007) 7431e7443intended lesion [13,14]. Drug carriers with a low biocompati-
bility are therefore recognized by the reticulo-endothelium
system (RES) located in the liver, spleen and lung, and elim-
inated from the blood circulation (Fig. 3). One strong incentive
to use macromolecular carriers is their preferential accumula-
tion in solid tumors. The accumulation of macromolecules in
tumors is currently explained by the microvascular hyper-
permeability of tumors to circulating macromolecules and
the impaired lymphatic drainage of macromolecules in these
tissues. This phenomenon, known as the ‘‘enhanced perme-
ability and retention’’ (EPR) effect [15e18], is very beneficial
because it results in the selective uptake of the polymer-
encapsulated drug by the tumor. In sharp contrast, healthy
tissues are exposed and damaged by non-encapsulated drugs
(Fig. 4).
For being used as a biomaterial, a polymer must be biocom-
patible. Biocompatibility was defined by Williams [19] as the
ability of a material to act with an appropriate host response in
a specific application. Moreover, biocompatible polymers used
in drug delivery are often biodegradable with formation of
non-harmful byproducts, such as non-toxic alcohols, acids
and other easily eliminated low molecular weight products.
Synthetic and natural biodegradable polymers [20e22] are
steadily more involved in pharmaceutical, medical and bio-
medical engineering. They can indeed contribute to the drug
release as a result of their erosion/degradation, in addition to
drug diffusion through the polymeric material.
Block copolymers are at the root of many drug delivery
systems, because their physico-chemical properties, such an
Fig. 1. Drug level in the blood with a controlled delivery dosing.amphiphilicity and degradation rate, can be tuned by the
choice, content and molecular weight of the constitutive
blocks.
2. Block copolymers in drug delivery systems
Distribution control is a key issue when the effectiveness of
a drug delivery system is concerned. It is indeed essential that
the drug delivery system is directed as precisely as possible to
the desired site of activity, and even better that the drug release
is triggered once this specific location is achieved.
The control of the drug distribution will be emphasized
hereafter for block copolymers, bioeliminable if not
biodegradable.
As aforementioned, once injected, drug delivery carriers are
rapidly removed from the bloodstream as a result of interac-
tion with the mononuclear phagocyte system (MPS) or with
the complement system [13,14]. In this respect, the properties
of the nanocarrier are of utmost importance because they de-
cide for or against interaction with plasmatic proteins and
cell membranes, and they can also impart some selectivity to
the drug distribution.
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Fig. 2. Schematized polymeric nanocarriers: (A) micelle, (B) nanoparticle and (C) liposome.
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by surfactants, such as polyvinylic alcohol (PVA) or charged
polymers. They are recognized by the plasmatic proteins and
oriented towards the macrophages of the RES. They are appli-
cable to hepatic pathology [23e25].
Whenever the plasma proteins are not deposited on their
surface, the nanocarriers are not recognized by the RES and
they belong to the ‘‘second generation’’ of the sterically stabi-
lized nanocarriers. Their lifetime in the bloodstream may be
long, and they finally accumulate in tumors by the EPR effect,
thus as result of a ‘‘passive targeting’’. Poly(ethylene oxide)
(PEO), designated as poly(ethylene glycol) (PEG) when
capped by a hydroxyl group at both ends, is most commonly
used to modify the surface of carriers for making them
‘‘stealthy’’.
3. Long-circulating carriers: the remarkable behaviour
of poly(ethylene oxide)
Polycondensation of ethylene glycol leads to poly(ethylene
glycol) (PEG), whereas poly(ethylene oxide) (PEO) is
prepared by ring-opening polyaddition of ethylene oxide.
Because the polymerization mechanisms are not the same,
the molecular characteristics of PEG and PEO are different.
PEG is indeed an a,u-dihydroxyl polyether, with a molecular
weight which does not exceed 20,000 and a broad molecular
weight distribution. Being prepared by ‘‘living’’ anionic
polymerization, the molecular weight of PEO is basically con-
trolled by the monomer/initiator molar ratio and the monomer
conversion, the polydispersity is low, and the a end-group is
the initiator fragment and the u end-group is a hydroxyl
group. In spite of these structural differences, PEO and PEG
are often used indiscriminately in the scientific literature.
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Fig. 4. Anatomical differences between normal tissues and solid tumors.In addition to linearity, the polyether chains are non-ionic
and water-soluble. The water solubility is unlimited whatever
the chain length, at least up to temperatures slightly below
100 C. Then an inverse solubility-temperature dependence
is noted. Not only the polyetherewater interactions are strong,
but also the polymer can fit the tetrahedral water lattice, such
that all the lattice points are occupied either by water or by the
ether oxygen of PEO. The ethylene segments thus fill out
voids in the spacious water structure and minimally perturb
the structure of water itself.
Chains of poly(ethylene oxide) being uncharged and linear
without bulky side groups are very flexible compared to
polymers with bulky pendant groups (steric hindrance) or to
polyelectrolytes (steric and electrostatic hindrances). The flexi-
bility explains why a brush of this polymer is protein repellent
[26e28]. A volume restriction effect that results in a configu-
rational entropy loss can contribute, at least partly, to this re-
markable property (Fig. 5A). When a protein is approaching,
the PEO layer is compressed and less configurations are pos-
sible for the PEO segments in this interaction region. This
reduction in entropy increases the free energy, which accounts
for a net repulsion of the proteins. In the case where the pro-
tein penetrates the polyether brush, an excluded volume effect
can also be effective, which triggers repulsion by an osmotic
pressure effect. Although these repulsion phenomena are
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Fig. 5. Basic mechanisms involved in the protein resistance of PEO surfaces.
(Reproduced from Ref. [26] with permission.)
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PEO is the only water-soluble non-ionic polymer that exhibits
a highly efficient protein resistance. It is now accepted that the
high flexibility, and thus the high mobility, of PEO in water is
determinant for its ability to be protein repellent. Indeed, rap-
idly moving hydrated PEO chains on a surface create locally
a large excluded volume that prevents protein molecules
from approaching the surface and from being in contact with
it for a period of time long enough for irreversible adsorption
to occur (Fig. 5B). This explanation was qualitatively consis-
tent with the predictions by a mathematical modelling that
a high density of long PEO chains was the best condition
for an underlying hydrophobic surface to be protein resistant
[29,30].
An alternative explanation of the protein repulsion by PEO
chains was proposed by Vert and Domurado [31]. It is well-
known that albumin and PEG are compatible in phosphate-
buffered saline at room temperature and at concentrations
comparable to those measured on the surface of PEO seg-
ment-bearing species. In contrast, protein and PEG phase-
separate eventhough the protein concentration is much lower
[32,33]. Therefore, Vert and Domurado propose that for
PEO segments to generate the stealth effect, they must be
compatible with albumin, such that PEO-bearing macromole-
cules or surfaces look like native albumin. This hospitality of-
fered by PEG macromolecules or PEO segments to albumin,
which is the dominant plasma protein, results in a ‘chameleon’
effect that prevents the activation of other PEG-compatible or
-incompatible plasma proteins or cells involved in foreign
body recognition and elimination.
Gref et al. [34] optimized the thickness and density of a
PEO coating at the surface of biodegradable poly(lactic
acid) (PLA) nanoparticles, in order to reduce simultaneously
surface charge, plasma protein adsorption, and interaction
with phagocytic cells. They observed a sharp decrease in the
protein adsorption upon increasing the molecular weight of
the polyether chains from 2000 to 5000 g/mol. Compared to
PEO(2K)ePLA(45K), the amount of adsorbed proteins onto
PEO(5K)ePLA(45K) particles was decreased by more than
50% . The plasma protein adsorption did not change signifi-
cantly with further increase in the PEO length (Fig. 6A). A
PEO content lying between 2 and 5% was the threshold value
for optimal protein resistance (Fig. 6B). On the assumption
that all the PEO chains form a brush (Fig. 7), the distance
between near neighbour chains on the PLA surface would be
approximately 1.4 nm. Consistently, Lee et al. [35,36] ob-
served that the adsorption of blood proteins (albumin,
g-globulin, fibrinogen) at the surface of poly(MMA-co-
MPEOMA) copolymers decreased with increasing PEO
molecular weight and MPEOMA content in the copolymers.
Peracchia et al. [37] showed that the protein adsorption was
also affected by the conformation of the PEO chains, particu-
larly by the immobilization of one or the two chain-ends of
PEO to the solid surface. The adsorption of plasma proteins
on a known amount of poly(ethylene oxide)-b-poly(isobutyl-
cyanoacrylate) nanoparticles was indeed more effectively
prevented by loops of PEO than by dangling chains [38].Fig. 8a tentatively schematizes the better protection of the
surface by the folding back of the protective PEO chains.
The effect of the architecture of the copolymer precursor of
the nanoparticles on their stealthiness was investigated by
Rieger et al., who compared PEO-b-PCL block copolymers
and PCL-g-PEO graft copolymers with a gradient structure
[39]. In a gradient-type graft copolymer, the PEO grafts are
A
B
PL
A5
0
PE
G
2-
PL
A4
5
PE
G
5-
PL
A4
5
PE
G
10
-
PL
A4
5
PE
G
15
-
PL
A4
5
PE
G
20
-
PL
A4
5
P
r
o
t
e
i
n
 
a
m
o
u
n
t
 
(
c
p
m
)
2000
1600
1200
800
400
0
2000
1600
1200
800
400
0
PL
A5
0
PE
G
-P
LA
0.
5%
PE
G
-P
LA
2%
PE
G
-P
LA
5%
PE
G
-P
LA
8%
PE
G
-P
LA
11
%
PE
G
-P
LA
16
%
PE
G
-P
LA
20
%
P
r
o
t
e
i
n
 
a
m
o
u
n
t
 
(
c
p
m
)
Fig. 6. Total amount of adsorbed proteins at the surface of (A) PEO-b-
PLA(45K) nanoparticles with different PEO molecular weights and (B)
PEO-b-PLA nanoparticles with different PEO contents made by blending of
PEO(5K)-b-PLA(20K) with PLA(40K).The protein amount is expressed in
arbitrary units. Data are the average of two experiments. (Reproduced from
Ref. [34] with permission.)
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a function of the surface area.unevenly distributed along the PCL backbone. The grafting
density goes actually increasing from one PCL chain-end to
the other one. These gradient copolymers were superior to di-
blocks of comparable hydrophilicelipophilic balance (HLB)
in stabilizing PLA nanoparticles prepared by nanoprecipitation
and in repelling proteins (Fig. 8b).
All these examples show that nanometric polymeric parti-
cles covered by a layer of PEO chains can prevent the physi-
ological defence processes stimulated by intravenous
injections from being triggered, which accounts for a longer
residence time observed in the systemic circulation [40e42].
In this respect, the lifetime in the blood stream was increased
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Fig. 9. Distribution of PEO-b-PI-b-PEO at the liver and spleen, carcass and
blood at 2 and 24 h, after injection. (Reproduced from Ref. [45] with
permission.)and the accumulation in liver/spleen was decreased when
poly(lactide-co-glycolide) (PLGA) nanoparticles were surface
modified by polylactide-b-poly(ethylene oxide) copolymers
[43,44]. Rolland et al. [45] studied the distribution of poly-
(ethylene oxide)-b-poly(isoprene)-b-poly(ethylene oxide),
PEO-b-PI-b-PEO, micelles intravenously injected in mice by
measuring the radioactivity of the blood samples. Fig. 9 shows
that the percentage of the triblock in the blood remains high
after 2 h and even after 24 h, in agreement with a low uptake
by the liver and spleen.
4. Long-circulating carriers for passive targeting
As aforementioned, high molecular weight compounds,
such as polymer carriers, preferentially accumulate in tumor
tissues rather than in healthy ones. The higher porosity of tu-
mor vessels (pores from 10 to 500 nm) (Fig. 4) can account for
the perivascular accumulation of macromolecules. This ‘‘pas-
sive targeting’’ associated to the EPR effect [15e18] was illus-
trated by Kwon et al. [46], who injected doxorubicin (DOX) in
mice and measured the drug content in tumors. DOX is a DNA
intercalating agent that inhibits the RNA and DNA syntheses
and is commonly administered intravenously for treating
tumors. Cardiotoxicity of DOX is, however, a problem.
Fig. 10 shows that DOX does not spontaneously accumulate
in tumors, in contrast to DOX attached to poly(ethylene ox-
ide)-b-poly(aspartate) micelles. The PEO-PAsp-DOX conju-
gates not only circulated for prolonged periods of time but
their selectivity for tumors compared to heart was significantly
7436 K. Van Butsele et al. / Polymer 48 (2007) 7431e7443improved from 0.9 (% dose per gram of tumor) for DOX to 12
for the PEO-PAsp-Dox conjugate with a PEO molecular
weight of 12000 g/mol and a PAsp molecular weight of
2000 g/mol (Fig. 10).
The major benefit of protection of drug nanocarriers by
poly(ethylene oxide) is to increase the circulation time in the
blood flow. As a result, a certain required concentration of
drug carrier is maintained longer in the blood after a single
injection, which is beneficial to accumulation in areas with
affected (leaky) vasculature and targeting of areas with dimin-
ished blood supply and/or low concentration of a target ligand.
The effectiveness of long-circulating nanocarriers strongly
depends on the tailoring of PEO containing block or graft
copolymers, in relation to the ability of PEO to protect the
nanoparticles against the RES. As discussed in the next para-
graph, performances of polymer-based drug delivery systems
can be improved further by functional copolymers of a more
complex structure.
5. Functional copolymers for active targeting
Binding pilot molecules [47e50] to nanocarriers is
a straightforward way for improving the drug targeting. Poly-
mers have thus to be modified by ligands specific to tumor
sites, which may result in a higher selectivity compared to
the EPR effect. Several parameters influence the efficacy of
drug targeting, such as size of the target, blood flow through
the target, number of sites on the target that can bind the
drug carrier, number and affinity of targeting ligands on the
drug carrier, and multipoint interaction of the drug carrier
with the target. Therefore, there is a need for high yield syn-
thesis of biocompatible and biodegradable amphiphilic block
copolymers, whose end-group of the hydrophilic block is reac-
tive and easily converted into conjugates of pilot molecules.
As previously explained, PEO is the typical component of
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Fig. 10. Time dependence of the level of PEO-b-PAsp-DOX conjugates in
solid tumors: (C) PEO(12K)-b-PAsp(2K); (B) PEO(5K)-b-PAsp(2K); (-)
DOX. (Reproduced from Ref. [46] with permission.)the hydrophilic shell of nanocarriers, such that the synthetic
efforts have been oriented towards well-defined a,u-hetero-
telechelic PEO.
Because the anionic polyaddition of ethylene oxide is liv-
ing, initiation by an alkaline metal alkoxide that contains
a functional group, protected or not, is the best strategy to pre-
pare heterotelechelic PEO. This functional group will be the
a end-group of the chains to be used further for the anchoring
of the pilot molecules. A hydroxyl group is released upon
hydrolysis of the propagating chains, and used, as such or after
conversion, to initiate the polymerization of a second hydro-
phobic block. The initiation of the ring-opening polymeriza-
tion of lactones and lactides is, for instance, direct in the
presence of tin octoate.
The pilot molecule can be attached to the a-end of PEO
either directly by initiation [51,52] or in a post-polymerization
step. As an example of the first approach, Nakamura et al. [52]
initiated the anionic polymerization of ethylene oxide by one
hydroxyl group of properly protected sugar molecules (four
hydroxyl groups out of five were protected by an acetal), such
as 1,2,5,6-di-O-isopropylidene-D-glucofuranose (DIGL), 1,2,3,4-
di-O-isopropylidene-D-galactopyranose (DIGA), and 1,2-O-iso-
propylidene-3,5-O-benzylidene-D-glucofuranose (IBGL). PEO
was accordingly capped quantitatively by one saccharide on
a sugar position that was dictated by the protection step of
the hydroxyl groups. The regioselectivity of the sugar bonding
is actually of great importance, because the cell-involved bio-
recognition via glyco-receptors on the cellular plasma mem-
brane and the saccharide receptor is often a regioselective
process.
In the second approach, the initiator contains a protected re-
active group suitable for further grafting of the targeting unit.
Kataoka et al. [53e55] synthesized poly(ethylene oxide) with
an a-acetal end-group and an u-hydroxyl end-group by initi-
ating the anionic polymerization of ethylene oxide by potas-
sium 3,3-diethoxypropyl alkoxide. The acetal end-group was
then converted into aldehyde, followed by conjugation with
an amino derivative in aqueous media. The Schiff’s base
that was accordingly formed was easily converted to a second-
ary amine by reductive amination. This reaction pathway is
thus well-suited to the surface modification of nanocarriers
by amine containing targeting molecules, such as proteins
and peptides. Initiators with a protected amine were also
used to prepare poly(ethylene oxide) with a primary amine
end-group [56e58].
A variety of specific ligands can be attached to PEO, e.g.,
saccharides, peptides, antibodies, folic acid and transferrin.
The functionality and solubility of the ligand obviously dictate
the coupling reaction and the solvent to be used. Because most
ligands of interest are selectively soluble in water, water-toler-
ant reactions impose themselves, the most common ones being
reductive amination, thiolemaleimide coupling and peptidic
coupling. It must be noted that amphiphilic block copolymers
form micellar solutions in water, such that the coupling of the
pilot molecule to the PEO block is conducted at the surface of
preformed nanocarriers. It is then often a problem to separate
the modified nanocarrier from the reaction side-products. The
7437K. Van Butsele et al. / Polymer 48 (2007) 7431e7443choice of clean and quantitative coupling reaction is therefore
a concern. In the same vein, when the hydrophobic block is
a hydrolyzable polyester (PCL, PLA), the reaction conditions
must be mild enough for avoiding premature chain
degradation.
Unprotected sugars (lactose, galactose and mannose) were
grafted onto the surface of polymeric carriers through
a Schiff’s base followed by reductive amination in water.
Nagasaki et al. [59] synthesized a PEO-b-PLA copolymer
with the PEO block capped by an aldehyde end-group. Alde-
hyde containing micelles were prepared by the dialysis
method and reacted with p-aminophenyl-b-D-lactopyranoside,
the reductive amination being carried out with NaBH3CN. The
coupling yield of lactose was 76%, and no side-reaction was
observed. Although this strategy did not require protection/
deprotection steps of the saccharide, it did not promote regio-
selectivity, the lactose being 1-0 substituted. Coupling of
lactose through other positions, such as C-6 and C-2, was
also reported in the scientific literature [60,61]. Peptidyl ligand
[62,63] was also conjugated to micelles by the same strategy.
In this respect, the impact of the targeting ligand on the gen-
eral behaviour of the nanocarrier must be pointed out. Indeed,
the distribution of the same type of nanoparticles can be
strongly influenced by the peptidyl ligand, e.g., negatively
charge ligands [phenylalanine (Phe) and tyrosyleglutamic
acid (TyreGlu)] vs neutral ligand [tyrosine (Tyr)]. Although
the lifetime in the blood compartment was long, whatever
the peptidyl ligand, the uptake of the nanoparticles by the
liver and spleen was importantly decreased when they were
piloted by the anionic TyreGlu ligand rather than by the neu-
tral one. Clearly, the ligand can affect the surface properties of
the micelles with consequences on the non-specific organ
uptake.
Nasongkla et al. [64] successfully attached a cyclic penta-
peptide, c(Arg-Gly-Asp-D-Phe-Lys) (cRGDeSH), to the sur-
face of micelles formed by PEO-b-PCL diblocks, whose
PEO block was end-capped by a maleimide. cRGDeSH was
selected as the targeting ligand because of a high affinity for
the avb3 integrin, which is a cell-tumor surface moleculethat plays a key role in the endothelial cell survival during
angiogenesis.
The covalent attachment of antibodies to polymeric
micelles was also reported with the purpose to prepare immu-
nomicelles [65e68]. Roby et al. [66] modified PEOephos-
phatidylethanolamine (PEOePE) containing micelles by an
anticancer antibody that was attached by peptidic coupling
reaction [69]. The amino containing antibody was reacted
with the p-nitrophenylcarbonyl derivative of PEOePE, with
a yield lying between 75 and 100%.
Two methods were reported for the surface modification of
polymeric micelles by folic acid (folate) based on the solubil-
ity of this compound, not only in water but also in various
organic solvents: (i) preparation of surface-activated micelles
followed by reaction with folate molecules in water [70]; (ii)
end-capping of block copolymer by folate molecules in an
organic solvent (dimethylsulfoxide (DMSO), or dimethyl-
formamide (DMF)) followed by micellization [71e76]. Yoo
and Park [71] synthesized folate-conjugated PEO-b-PLGA
block copolymers by a peptidic reaction between folic acid
and the amino end-capped diblock, NH2-PEO-PLGA, in water.
Folic acid is a good candidate for tumor targeting because
of a high affinity for the folate binding protein (FBP)
(Kd< 1 nM), which is overexpressed on the surface of cancer
cells [77e80]. Therefore, folate-conjugates, which are not
transported to lysosomes like most ligands [81], can be di-
rected to cancer cells and internalized by receptor-mediated
endocytosis. They remain in recycling endosomes or escape
in the cytoplasm. Their intracellular behaviour after ligand-
mediated endocytosis thus distinguishes them from other types
of ligands, such as antibodies, hormones and peptides.
The obvious advantages of targeted carriers (active target-
ing) over non-targeted ones (passive targeting) are a shift of
the carrier distribution in favour of the tumor cell compart-
ment, a prolonged carrier retention in tumors and delivery of
the carrier content in an intracellular compartment. Oyewumi
et al. [78] compared the cell uptake and tumor retention of
gadolinium nanoparticles coated by folateePEO and PEO,
respectively. At a nanoparticle concentration of 180 mg/ml,TimeTemperature of Incubation
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Fig. 11. (A) In vitro uptake of folateePEO-coated nanoparticles (,) and PEO-coated nanoparticles (-) after incubation (180 mg/ml, 37 C, 30 min) with KB
cells. Each value is an average of three data standard deviation. (B) Retention of folateePEO-coated (,) and PEO-coated (-) nanoparticles after injection
into KB tumors developed in athymic mice. After 8 and 24 h, the mice were sacrificed, and the amount of Gd NPs in the tumor was measured by a gamma counter.
Each value is an average of 6e7 data standard deviation. (Reproduced from Ref. [78] with permission.)
7438 K. Van Butsele et al. / Polymer 48 (2007) 7431e7443the KB cell uptake of folateePEO-coated nanoparticles was
20-times higher than that of PEO-coated nanoparticles after
30 min of incubation (Fig. 11A). In parallel, the retention of
folateePEO-coated nanoparticles and PEO-coated ones was
analyzed in vivo, thus in tumor tissue, 8 and 24 h after an intra-
tumor injection. Statistically larger amounts of folateePEO-
coated nanoparticles were retained in tumor tissues compared
to PEO-coated nanoparticles (Fig. 11B).
6. Responsive copolymers for smart targeting
According to the aforementioned examples, the intracellu-
lar delivery of anticancer drugs is improved and thus drug is
delivered into the cytoplasm, whenever low molecular weight
endogenous ligands and cell penetrating peptides are immobi-
lized at the periphery of drug nanocarriers. This internalization
process is a prerequisite for the killing of cells, because most
cytotoxic drugs act intracellularly. As a rule, the non-specific-
ity of ligands is responsible for death of a non-negligible
amount of normal cells, which is a major concern in tumor tar-
geting. An answer to this problem is in the use of pH-respon-
sive polymers. Indeed, the extracellular pH of tumors is
a consistently distinguishing phenotype of most solid tumors
compared to surrounding normal tissues [82]. The experimen-
tal pH of most solid tumors in patients ranges from 5.7 to 7.8,
with a mean value of 7.0. More than 80% of the experimental
data are below pH 7.2, while blood pH remains constant at 7.4.
Moreover, after cellular uptake, the drug carrier reaches the
lysosomes with an even more acidic environment (lysosomial
pH of 4.5e5.0).
Although they are typical pH-responsive polymers, poly-
cations can be toxic [83]. As a rule, neutral polymers and
polyanions are less cytotoxic than polycations, merely
because most of the proteins are negatively charged, which
restricts their adsorption. Expectedly, polycations with higher
molecular weight and higher cationic charge density interact
more importantly with cell membranes and cause cell dam-
age. Surface electrical charge may also have an impact on
the biocompatibility. Cationic macromolecules and their
drug conjugates are indeed rapidly eliminated from plasma,
in contrast to weakly anionic macromolecules that have
a long circulation life [84].6.1. pH-triggered ligand exposure
pH-sensitive multifunctional polymeric micelles with non-
specific ligands which are exposed only under slightly acidic
conditions (6.5< pH< 7.0) were recently prepared. This spe-
cific exposure to tumor cells has the advantage that the ligands
may be non-specific and it may be chosen for internalization
of the nanocarrier.
As an example, Sawant et al. [85] prepared and tested in
vitro PEGylated drug delivery systems (liposomes and mi-
celles) that contained a non-specific internalization function
(biotin or TAT peptide). This function was shielded by PEO
under normal conditions, which strongly restricts internaliza-
tion in normal cells, but it was exposed upon brief incubation
at lower pH which speeds up the internalization in tumor cells
(Fig. 12). This system consists of mixed micelles prepared
with at least two surfactants: (i) a PEO-hydrazone-phosphati-
dylethanolamine (PEO-Hz-PE) surfactant, whose hydrazone
junction between the hydrophilic tail and the hydrophobic
head is cleaved by acidic hydrolysis, (ii) a biotinePE shorter
amphiphile which is part of the PEO shell.
In a similar approach, Sethuraman and Bae [86] prepared
smart micellar nanocarriers in which the non-specific TAT
peptide was not detected in normal tissues as result of the in-
ter-polyelectrolyte complex association of PLA-b-PEO-TAT
micelles with an ultra pH-sensitive smart block copolymer,
polysulfonamide-b-PEO (PSD-b-PEO). Indeed, the posi-
tively-charged TAT exposed at the surface of the micelles
was shielded by complexation with the polyanionic sulfon-
amide block (PSD) of the copolymer. This nanocarrier was
merely prepared by the physical mixing of the two compo-
nents. The PSD component is negatively charged at pH 7.4
and neutral below pH 7.0 (extracellular tumor pH), so that
the TAT micelles are deshielded at the lower pH of the tumor
environment. Once again, the TAT peptide contributes to the
targeting of the drug loaded micelles into the cells and nuclei
where the cytotoxic effect takes place (Fig. 13). The fate of
TAT micelles and TAT micelles complexed by PSD-b-PEO
at pH 6.6 and 7.4 was comparatively analyzed in vitro by
flow cytometry. After 30 min of incubation, the TAT micelles
were taken up by the cells in contrast to the complexed ones
that remained uncaptured. After 1 h, the micelles complexedTargeting by target specific antibody
and/or long circulation
a  a  a a   a  a  a a
b b
c
Incubation at lowered pH
Removal of PEG chains
De-schielding of the « hidden » function
b b
c
a
a
a
a
a
a
a
a
Fig. 12. Schematized multifunctional nanocarriers including: (a) pH-cleavable PEO-Hz-PE, (b) temporarily ‘‘shielded’’ biotin or TAT peptide, and (c) monoclonal
antibody attached to the surface of the system through a pH-uncleavable spacer. (Reproduced from Ref. [85] with permission.)
TAT
PEG Chain
Poly sulfonamide
Dissociated Poly
sulfonamide
(a) (b)
Fig. 13. (a) At normal blood pH, the sulfonamide is negatively charged, and complexes the positively-charged TAT exposed at the surface of the micelles. Only
PEO is exposed to the outside which makes the carrier long circulating. (b) When the system experiences a decrease in pH (near tumor), sulfonamide loses charge
and is released, thus exposing TAT to interaction with tumor cells. (Reproduced from Ref. [86] with permission.)
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complexed by PSD-b-PEO at pH 7.4 had not entered the cells.
The PSD-b-PEO chains are thus able to shield effectively the
TAT peptide at pH 7.4.
6.2. pH-triggered micelles destabilization
The drug release from polymeric micelles can also be trig-
gered by a change in pH [87,88]. The local drug delivery by
the micellar carriers can indeed be improved by the destabili-
zation of the micelles in pathological tissues of a lower
pH, thus by combining the EPR effect with stimulus-
responsiveness.
pH-sensitive block copolymer micelles [82,89,90] and
nanoparticles [91e93] prone to dissociation when accumu-
lated at the tumor sites and/or entered the cytoplasm were de-
signed as schematized in Fig. 14a. Lee et al. [89] prepared
pH-sensitive micelles of PEO-b-poly(L-histidine) (PEO-b-
PHis). The hydrophobic imidazole of the histidine repeat units
is protonated at the tumor extracellular pH (pH 7.2), so
making the PHis block hydrophilic and destabilizing the
long-circulating polymeric micelles with release of the drug.
The adriamycin release by the PHisePEO micelles was indeed
accelerated by a pH decrease from 8 to 6.8 (Fig. 15, circles).
The sensitivity of the polymeric micelles to the more acidic
extracellular pH of tumors was modulated, and the micelle sta-
bility at pH 7.4 was improved by preparing mixed micelles
consisting of PHis-b-PEO and PLLA-b-PEO block copoly-
mers, with or without a folate ligand [82,90]. This hybridiza-
tion of the micelles shifted the triggering pH to lower values
(7.2e6.6) (Fig. 15).
An even more elaborated systems combined the strategies
discussed in the subsections 6.1 and above [94]. Mixed
micelles of two block copolymers, i.e., poly(L-histidine)-b-
poly(ethylene oxide) (PHis-b-PEO) and poly(L-lactic acid)-b-
PEO-b-PHis-biotin, were prepared. Both the PHis and the
PLLA blocks formed the core of the micelles, and PEO was
the shell. Because of the high water solubility of PEO and bi-
otin, the short PHis block in the PLLA-b-PEO-b-PHis-biotin
copolymer was located at the coreeshell interface, which
caused the bending of the PEO block and the preferential lo-
cation of biotin in the PEO shell built up by the PHis-b-PEOblock copolymer (Fig. 14b). The micelles were stable above
pH 7.2 and hided the conjugated biotins. At pH below 7.2,
PHis was ionized, which was detrimental to the hydrophobic
interaction of PHis with the micellar core. As a result, the
PEO-b-PHis-biotin expanded, and biotin was exposed out of
the PEO shell. The micelles degradation being also pH depen-
dent, the release of doxorubicin was enhanced at the early
endosomal pH (Fig. 14c).
Micelle core (pLLA + polyHis)
pH>7.0 pH<6.5
PEG
PolyHis (1K)
biotin
(a)
(b)
(c)
6.5<pH<7.0
PEG shell
pH≥7.4
pH<7.4
Fig. 14. Schematic illustration of (a) pH-triggered destabilization of micelles
and (b and c) pH-triggered ligand exposure. Above pH 7.0, biotin (which is
anchored to the micellar core through a pH-sensitive chain actuator (polyHis))
is shielded by a PEO shell. At 6.5< pH< 7.0, biotin is exposed at the micellar
surface and can interact with cells, which facilitates biotin receptor-mediated
endocytosis. Upon a further decrease in pH (pH< 6.5), the micelles are desta-
bilized, which results in enhanced drug release and disruption of cell mem-
branes, such as endosomal membranes. (Reproduced from Ref. [94] with
permission.)
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made of poly(L-lactide)-b-poly(2-ethyl-2-oxazoline)-b-poly(L-
lactide) (PLLA-PEOz-PLLA) triblock copolymer. In a similar
approach, Hsiue et al. [96] used poly(2-ethyl-2-oxazoline)-b-
poly(L-lactide) (PEOz-PLLA) diblock copolymer. PEOz is
a pH-sensitive polymer with a low cytotoxicity and a favour-
able pKa close to neutral pH. The release profiles of DOX-
loaded micelles were different in neutral and acidic buffer
solutions. Compared to triblock copolymer micelles, micellar
diblock copolymers offered several advantages, including
easy preparation, smaller DOX-loaded micelles, improved
micellar structure and sharper pH-response and drug release.
6.3. pH-cleavable drugepolymer conjugates
Rather than using a targeting ligand, an alternative
approach may be found in the covalent linkage of the drug
to the carrier, however, through a hydrolyzable bond. The tar-
geting of tumor tissue relies again on a pH effect, i.e. the
cleavage of the drug-carrier bond at low pH, particularly in
the lysosomes of tumor cells.
Cis-aconityl acid, Schiff’s base derivatives and hydrazones
are the most prominent acid-labile linkers which have been
used in these pH-triggered release systems [97e99]. Because
hydrazone is cleaved within a short period of time in an acidic
environment, Bae et al. [100] synthesized an amphiphilic
block copolymer PEO-b-poly(aspartate-hydrazone-adria-
mycin) (PEO-b-p(Asp-Hyd-ADR) and prepared micelles
therefrom. The ADR release by the micelles was dependent
on time and pH (in the 7.4e3.0 range). Although the micelles
were stable under physiological and early endosomal con-
ditions, the ADR was gradually released considering that pH
in late endosomes and/or lysosomes in the cells is w5.0, so
fitting the conditions of effective cleavage of hydrazone.
The superiority of this approach over the previous one
(Section 6.2) is that the covalent anchoring of the drug totally
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Fig. 15. pH-dependent cumulative ADR release from mixed micelles of poly-
His-b-PEO and PLLA-b-PEO (PLLA-b-PEO content in the mixed micelles):
() 0 wt.%, (-) 10 wt.%, (:) 25 wt.% and (;) 40 wt.% after 24 h. (Repro-
duced from [82] with permission.)prevents its release under physiological conditions. However,
attention must be paid to the possible alteration of the thera-
peutic activity of the drug as a consequence of the chemical
grafting.
7. Biodegradation issue
Once injected, there is no choice for the nanocarrier but to
accumulate in the body after drug release, which may be
a problem sooner or later. This explains why biodegradable
and/or bioeliminable polymers are unavoidably used in the
design of drug nanocarriers [2,20e22].
Although biodegradation results from a biological activity,
particularly from an enzymatic action, all the polymers said
‘‘biodegradable’’ in the literature do not fit this definition.
At the time being, the hydrophobic constitutive component
of known medical devices and controlled release formulations
is an aliphatic polyester selected for biocompatibility and
degradability. They are bioresorbable after hydrolytic degrada-
tion followed by bio-assimilation or elimination of degrada-
tion-byproducts.
Homo- and copolymers of lactic acid (LA) and glycolic
acid (GA) are being extensively used in controlled release car-
riers because of high degradation rate [21]. They are com-
monly synthesized by ring-opening polymerization of lactide
and glycolide, respectively, at 140e180 C with a tin catalyst
[101e104], particularly tin 2-ethylhexanoate, which is ap-
proved by FDA as a food stabilizer.
These aliphatic polyesters are degraded by bulk hydrolysis
of the ester bonds on a timescale of weeks. PLA is not only an
excellent biomaterial but also safe for in vivo application
because it is degraded into lactic acid, which is a natural
metabolite of the body. PLA has also an excellent loading
capacity and the drug release is mediated by the non-enzy-
matic hydrolysis, which is autocatalyzed by the carboxylic
acid end-groups of the chains.
PCL is also well-suited to controlled drug delivery because
of high permeability to many drugs and non-toxicity. Its deg-
radation is, however, much slower (year timescale) than PLA
and PGA, which makes it less common in delivery nanocar-
riers. Nevertheless, the degradation rate can be extensively
modulated by copolymerization of LA with glycolide and
3-caprolactone (3-CL). The degradation kinetics of PLA is
indeed increased by glycolide and decreased by 3-CL, to an
extension that depends on the comonomer content.
Although not biodegradable, PEO is eliminated from the
body by the natural filtration when the molecular weight
does not exceed 40,000 g/mol. So, self-assembly copolymers
of PEO and aliphatic polyesters do not accumulate in the
body even in case of repeated injections, which makes them
very attractive as materials for building-up nanocarriers.
8. Conclusion
Nowadays, effective drug delivery systems are emerging as
result of a more accurate targeting of pathological tissues.
7441K. Van Butsele et al. / Polymer 48 (2007) 7431e7443Indeed, higher doses are released at the desired sites, with less
damage for healthy tissues. This substantial progress is the
consequence of the steadily improved understanding of the
biological and chemical impacts of disease at the molecular
level, the new therapeutic concepts accordingly devised, and
their implementation by the design of intelligent drug nanocar-
riers. The engineering of synthetic polymers play a key role in
the building-up of these polymeric nanocarriers that basically
results from the self-assembly of amphiphilic block copoly-
mers into stealthy micellar drug reservoir guided to tumor
tissues, where the drug is selectively released.
This review has emphasized the prominent role of poly-
(ethylene oxide) in the construction of nanocarriers circulating
in the blood stream for a long time and how a passive targeting
is effective because of natural anatomic differences between
tumors and normal tissues. Performances of cancer treatment
have been improved by the more accurate tailoring of PEO
containing amphiphiles, which increased the complexity of
the nanocarriers at the benefit of the active targeting. The
recent advent of pH-sensitive nanocarriers has improved
further the control of the drug distribution and bioavailability.
Last but not least, the proper choice of the constitutive compo-
nents of the polymeric amphiphiles takes into account the
bioelimination of the carrier after the drug delivery.
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